Your access to bioidentical hormone replacement therapy (BHRT) is in serious jeopardy—again. Legislation is making its way through Congress that would give the Food and Drug Administration unprecedented control over compounding pharmacies that make BHRT.
Five years ago, the FDA tried to ban the most commonly compounded BHRT treatments. The agency failed because it did not have the authority to do so. This bill gives the FDA authority to do that and much more. It’s that simple. Physicians and patients alike must tell Congress that you do not want the federal government involved in the prescriber/patient relationship and telling doctors how to run their practices.